| Business Summary | | Demegen,
Inc.
discovers,
designs,
and
develops
novel
peptides,
proteins
and
genes
for
the
treatment
of
cancer,
cystic
fibrosis,
multi-drug
resistant
bacteria
and
fungi.
In
addition
to
pharmaceutical
products,
applications
include
genetically
enhanced
agricultural
products.
Dow
AgroSciences
LLC
has
licensed
two
broad
agricultural
applications.
Demegen
expects
to
initiate
human
clinical
trials
for
pharmaceutical
applications
during
the
fourth
quarter. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Demegen,
Inc.
designs
unique
molecules
which
have
antimicrobial
characteristics.
The
Company's
products
are
peptides
or
peptide-like
molecules.
DBOT
also
designs
genes
to
confer
disease
resistance
or
improve
nutritional
value.
For
the
nine
months
ended
6/30/01,
revenues
rose
34%
to
$946
thousand.
Net
loss
app.
to
Com.
totalled
$6.1
million,
up
from
$1.4
million.
Results
reflect
increased
grant
and
license
fees
and
increased
amort.
expenses
related
to
deferred
license
fees
with
Periodontix. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Richard Ekstrom, 56 Chairman,
Pres | $165K | Jesse Jaynes, Ph.D., 49 VP,
Research, Chief Scientist | 132K | Mary Silverberg, 56 Sec. | -- | S. Robert Fatora, 56 COO
-- Pharmaceutical Products | 366K | Dollar amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|